{
    "clinical_study": {
        "@rank": "129305", 
        "acronym": "FACT", 
        "arm_group": {
            "arm_group_label": "Group A", 
            "description": "Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice"
        }, 
        "brief_summary": {
            "textblock": "French epidemiological data have shown a heterogeneous distribution of the risk of mortality\n      from prostate cancer according to region. The main objective is to describe the distribution\n      of prostate cancer stages when first line hormonal therapy is introduced (overall and by\n      region)."
        }, 
        "brief_title": "Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically demonstrated prostatic adenocarcinoma.\n\n          -  Patients never previously treated with hormonal therapy for prostate cancer.\n\n          -  Patients eligible for hormonal therapy after initial consultation (alone or in\n             combination with curative treatment).\n\n          -  Patients agreeing to the collection of personal health data for the purposes of the\n             study.\n\n          -  Patients with locally advanced or metastatic prostatic cancer tumours or a biological\n             recurrence after curative treatment.\n\n        Exclusion Criteria:\n\n          -  Patients participating in a clinical study involving prostate cancer at the time of\n             inclusion in the investigation.\n\n          -  Patients having received or currently receiving hormonal treatment for prostate\n             cancer (surgical castration or other hormonal manipulation, including GnRH receptor\n             antagonists, antiandrogens, oestrogens, 5 alpha reductase inhibitors)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Men never previously treated with hormononal therapy for prostate cancer"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01729676", 
            "org_study_id": "000059"
        }, 
        "intervention": {
            "arm_group_label": "Group A", 
            "description": "Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice", 
            "intervention_name": "Degarelix or GnRH agonist", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Deslorelin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Libourne", 
                    "country": "France"
                }, 
                "name": "H\u00f4pital Robert Boulin"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation: FACT STUDY", 
        "overall_contact": {
            "email": "DK0-Disclosure@ferring.com", 
            "last_name": "Clinical Development Support"
        }, 
        "overall_contact_backup": {
            "last_name": "There may be other sites in this country"
        }, 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: National Consultative Ethics Committee for Health and Life Sciences", 
                "France: French Data Protection Authority"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The stages of prostate cancer are classified as locally advanced, metastatic and biological recurrence.", 
            "measure": "Estimated percentage of different prostate cancer stages (overall and by region)", 
            "safety_issue": "No", 
            "time_frame": "During a single consultation when first-line prostate cancer hormone therapy is started"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01729676"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Characteristics are described by demography, tumour characteristics, Gleason score, D'Amico score, prostate specific antigen (PSA), Testosterone and treatment history", 
                "measure": "The characteristics of the patients with prostate cancer by region", 
                "safety_issue": "No", 
                "time_frame": "During a single consultation when first-line prostate cancer hormone therapy is started"
            }, 
            {
                "description": "The regional influence will be demonstrated by modelling the probability of a patient being at one of the cancer stages (locally advanced cancer, metastatic cancer, biological recurrence).", 
                "measure": "The influence of regional factors on staging of prostate cancer", 
                "safety_issue": "No", 
                "time_frame": "During a single consultation when first-line prostate cancer hormone therapy is started"
            }
        ], 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}